Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Oct 15, 2021 1:35pm
170 Views
Post# 34010675

RE:RE:RE:RE:RE:RE:RE:I have complaints

RE:RE:RE:RE:RE:RE:RE:I have complaints

I don't mind reading tea leaves as long as we know that it what we are doing.

I might be wrong but my general expectation is efficacy develops over time and the reality is we are still early in the process. So not having something to say on efficacy is acceptable at this point.

Paul again said things are directionally correct (he said it about NASH). I read that statement to mean there's no need to panic (yet). They updated safety and generally what they said fits with safety being "directionally" fine. If they had said anything around efficacy, even just patients experiencing some stability for now then I'd probably be happy to extend directionally correct to cover efficacy. They didn't say anything on efficacy so I'm not letting directionally correct cover efficacy for now. None of this rules out the possibility of getting some efficacy by the end of the year.

I just don't believe they have anything meaningful yet because I think that would have been in the update.


PWIB123 wrote: I don't see a do-nothing approach as reasonable in spite of waiting on confirmation of certain milestones.  There is a balance here.  Your scientific perspective certainly keeps the scenario grounded in reality, but there's no risk-reward scenario in waiting for guaranteed outcomes.  And thus, we must speculate!  I personally highly value the reading of the tea leaves.  

 

<< Previous
Bullboard Posts
Next >>